Dr. Alexander “Sandro” Sulakvelidze, Ph.D., is the President and CEO of Intralytix, Inc. Dr. Sulakvelidze is an internationally recognized expert in phage technology who was instrumental in securing the first ever FDA approval for a phage-based food safety product in the world. He has published extensively about phage biocontrol and phage therapy and has pioneered the approach of using bacteriophages for modulating the human microbiome. Dr. Sulakvelidze served as founding Editor-in-Chief of the journal Bacteriophage, and he also co-edited a major book about bacteriophages published by the CRC Press. In 1998, Dr. Sulakvelidze co-founded Intralytix, Inc., a pioneer, United States company developing and commercializing bacteriophage-based products for a variety of clinical and agricultural applications designed to maintain and improve animal and human health. He has been serving in different senior management positions in the Company since, until becoming President and CEO of Intralytix in 2020.